Fennec Pharmaceuticals Inc. (FENC) Q4 2025 Earnings Call

Concluded Mar 24, 2026

Mar 24, 2026 0 turns

Period: FY2025 Q4
Runtime: —
Sources: 2 artifacts

8-K 10-K

Executive readout · one minute

Call research workspace

Read the call alongside every captured source. 8-K earnings release, 10-K stay in one workspace.

Pedmark label and lifecycle 38 Label expansion opportunities 23 Financial performance and outlook 22 International / Pedmar Q launch 9 Commercial expansion / Project Ignite 8 Investigator-initiated studies / clinical momentum 8

Management tone

Confident

Net tone +62 · moderate hedging

Grounding quotes

“We are encouraged by our strong start to the year and believe 2026 is a defining period for Fennec.”
“we believe we are well positioned to deliver sustained growth throughout this year.”
“we're enthusiastic about what we're seeing with Norgene. And it's, you know, this is the year we'll see significant growth in Norgene throughout their territories.”
“we believe our first quarter performance reflects meaningful momentum across the business and reinforces our confidence in 2026 as an important year for Fennec.”

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Revenue · derived Q4 $13.78M +73.8% YoY

Net income · derived Q4 -$4.79M

Research materials

Open the source you need; every reader stays inside this workspace.

8-K earnings release Filed Mar 24, 2026 10-K report Filed Mar 27, 2026 Company webcastOpen the original investor-relations page

Read transcripts like this one from Claude, ChatGPT or your own code with the earnings call transcript API →